Dr. Charles Mok argues testosterone reduces breast cancer risk and recurrence in women. The FDA approved it for metastatic breast cancer in the 1950s, and studies show a 28-70% reduction in incidence when used for menopause symptoms, sometimes without estrogen.
Chapters
Testosterone, it turns out, has been FDA approved for women for breast cancer metastatic breast cancer since the 50s. In fact, testosterone is the hormone in which the drug tamoxifen was somewhat based on to block estrogen receptor positive breast cancer. Testosterone does reduce the risk of breast cancer, recurrence and development of breast cancer. Large studies done in the United States and to some degree in Europe have shown that testosterone as a primary solution for menopause had a significant reduction in the incidence of breast cancer and reduction is anywhere from about 28% to 70% depending how long the studies run in different factors, but a significant reduction in menopausal symptoms with or without the concomitant use of estrogen.